Ratner Lee
Division of Molecular Oncology, Washington University, 660 South Euclid Avenue, Saint Louis, MO 63110, USA.
Curr Opin Oncol. 2005 Sep;17(5):469-73. doi: 10.1097/01.cco.0000174037.84903.fb.
This article summarizes the current pathophysiologic basis for human T cell lymphotropic virus-associated leukemia/lymphoma as well as past, present, and future therapeutic options.
New studies have been published on allogeneic stem cell transplantation, arsenic trioxide, and bortezomib for this condition.
Studies of the molecular biology of human T cell lymphotropic virus-1-induced T cell leukemia/lymphoma have defined a critical role for oncoprotein, Tax, and activation of nuclear factor kappaB transcription pathways, which have provided rational approaches to improved therapy for T cell leukemia/lymphoma as well as a model for other hematopoietic malignancies characterized by nuclear factor kappaB activation.
本文总结了人类嗜T细胞病毒相关白血病/淋巴瘤当前的病理生理基础以及过去、现在和未来的治疗选择。
已发表了关于同种异体干细胞移植、三氧化二砷和硼替佐米用于该疾病的新研究。
对人类嗜T细胞病毒1型诱导的T细胞白血病/淋巴瘤的分子生物学研究确定了癌蛋白Tax以及核因子κB转录途径激活的关键作用,这为改善T细胞白血病/淋巴瘤的治疗提供了合理方法,并为其他以核因子κB激活为特征的造血系统恶性肿瘤提供了模型。